Market Overview

Novartis Division Alcon Receives FDA Approval for AcrySof®IQ Aspheric IOL with UltraSert Pre-loaded Delivery System

Share:
Related NVS
8 Firms To Debut On The Markets This Week
Gilead's Yescarta Cancer Treatment Approved, Some Analysts Shrug

Alcon, the global leader in eye care and a division of Novartis (NYSE: NVS), has received US Food and Drug Administration (FDA) approval for its AcrySof® IQ Aspheric IOL with the UltraSertTM Pre-loaded Delivery System for patients undergoing cataract surgery. This new delivery system combines the control of a manually loaded device…Alcon, the global leader in eye care and a division of Novartis, has received US Food and Drug Administration (FDA) approval for its AcrySof® IQ Aspheric IOL with the UltraSertTM Pre-loaded Delivery System for patients undergoing cataract surgery. This new delivery system combines the control of a manually loaded device with the safety and convenience of a disposable, pre-loaded injector to optimize the implantation of the AcrySof IQ Aspheric IOL into the cataract patient's eye. Nearly four million cataract surgeries are performed each year in the US[1]. The UltraSertTM Pre-loaded Delivery System received the European CE mark in June 2015.

See full press release

Posted-In: News FDA Press Releases

 

Related Articles (NVS)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...